A dominant surgical-robotics “razor-and-blade” ecosystem—now layering in digital subscriptions—drives durable compounding, with China and capital budgets the main swing factors.
Overview
Intuitive Surgical is the pioneering, category-defining leader in robotic-assisted minimally invasive surgery, with a durable “razor-and-blade” business model built on system placements that drive recurring procedure revenue. By early 2026, ISRG surpassed 20 million lifetime procedures, including ~3.2 million in FY2025, underscoring the scale of its installed-base flywheel. FY2025 revenue reached ~$10.06B (+21% YoY) with strong operating leverage (GAAP operating income ~$2.95B, +25%). Recurring revenue (instruments/accessories and services) is the core strength, representing ~81% of Q4 2025 revenue and providing high predictability. The portfolio is anchored by da Vinci 5 (multi-port), da Vinci SP (single-port), and Ion (lung biopsy), increasingly augmented by a digital ecosystem (MyIntuitive Plus). Key growth vectors are the da Vinci 5 replacement cycle, expanding procedure adoption (especially general surgery and ASCs), and scaling Ion globally, while primary risks include China tenders, tariffs, cybersecurity, and hospital capital constraints.